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Abstract 
Increased protein production is a prerequisite for cell proliferation, thus rendering 
translation and ribosome deregulation a common hallmark of cancer cell biology. A 
frequently observed mechanism in malignancies is the overactivation of the 
translational process. As a consequence, strategies that selectively target the 
ribosomal machinery bear significant promise as cancer therapeutic approaches. To 
this end, this report provides a workflow for the identification of novel miRNA 
molecules with the ability to target and suppress ribosomal activity in cancer cells.  
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Abbreviations: 
RPs: Ribosomal Proteins 
rRNAs: Ribosomal RNAs 
miRNA: MicroRNA 
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Ribosomes are the main molecular 
machines responsible for protein 
synthesis within the cells of all 
domains of life. Each ribosome is 
composed of 80 Ribosomal Proteins 
(RPs) and 4 Ribosomal RNAs (rRNAs) 
which assemble into two subunits 
within the nucleolus. After their export 
to the cytoplasm, the 40S and 60S 
subunits work together to convert 
genetic information into protein with 
both speed and accuracy.  
Cancer cells reside in a permanent and 
uncontrolled cellular proliferation 
state. This trait induces a pressing need 
for protein production, which is crucial 
in order to support the incremented 
metabolic needs of the rapidly 
duplicating cells (Sulima et al., 2017). 
As a consequence, ribosomal function 
is often modulated in cancer cells with 
alterations mainly directing towards 
one or both of the following pathways: 
1) to increase the abundance of the 
ribosomal machinery (and therefore 
protein synthesis); and/or 2) to reduce 
the translational accuracy (fig. 1A) 
(Topisirovic and Sonenberg, 2015, 
Tahmasebi et al., 2018, Robichaud et 
al., 2018). A notable example of the 
first mechanism is mediated via the 
oncogene MYC. The latter, is 
frequently amplified in various human 
cancers, where it has been shown to 
promote oncogenesis by acting as a 
direct transcriptional inducer of RPs 
genes (Robichaud et al., 2018). Alike 
MYC, additional factors, such as ΔΝ-
netrin-1 and the Epithelial Cell 
Transforming 2 (ECT2) oncogene, 
attain aberrant functionality within 
tumor cells and function as strong 
inducers of rRNAs, thus driving 
ribosome biogenesis and vastly 
increasing protein synthesis (Delloye-
Bourgeois et al., 2012, Huh et al., 
2003). Interestingly though, lesions 
such as mutations, deletions or 
downregulation of specific RPs have, 
also, been observed in various types of 
cancers and those, although not always 
clearly understood, are presumed to 
impair accuracy of translation (second 
mechanism, fig. 1A). Examples 
include specific mutations in ribosomal 
proteins, such as uL18/RPL5 which 
was found mutated in patients’ samples 
of glioblastoma (11%), melanoma 
(28%) and breast cancer (34%) 
(Fancello et al., 2017). Similarly, 
patients with acute lymphocytic 
leukemia repeatedly bear mutations in 
uL18/RPL5 and uL16/RPL10 (De 
Keersmaecker et al., 2013), whereas 
uS10/RPS20 mutations seem to play a 
role in the pathogenesis of a hereditary 
type of colorectal cancer (Nieminen et 
al., 2014). In summary, the entirety of 
the changes described above impair the 
central process of translation, thus 
inducing chaotic alterations in the 
cancer cell proteome, and ostensibly 
promoting cell multiplication, 
metastasis and resistance to therapy 
(fig. 1A).  
In this direction, targeting the aberrant 
and uncontrolled ribosomal machinery 
of the cancer cell may constitute an 
effective anti-cancer strategy (outlined 
in fig. 1B). To this end, we have 
developed a strategy and a workflow 
pipeline to identify miRNAs with the 
ability to bind to RPs, and therefore 
leverage the gene-suppressing nature 
of the interaction between miRNAs 
and their target genes. Our goal is to 
unravel novel molecules of 
pharmacological interest aiming to 
selectively suppress the impaired- 
frequently overactivated- translation 
process of the tumor cells and thereby 
render those cells vulnerable to cell 
death (fig. 1B). Notably, the versatile 
class of miRNAs may include very 
potent pharmacological candidates as 
evidently shown by the multiple 
clinical trials that investigate such 
therapies as well as the recent approval  
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Figure 1: Outline of the main aspects addressed in order to identify miRNAs with the ability 
to target the ribosomal machinery.  
A. Alterations in ribosomal function and oncogenesis. Oncogenic mutations affect ribosomal 
function via two main mechanisms: a) an increase in ribosome biogenesis (e.g. via the MYC 
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oncogene); and b) a reduction in translational fidelity (e.g. mutations in uL18/RPL5). Both 
mechanisms benefit cancer initiation and progression.  
B. Targeting the ribosomal machinery with miRNA molecules. The suggested approach 
includes the identification of miRNAs that target RPs, thus suppressing ribosomal function in 
cancer cells and inducing cell death.  
C. List of the miRNAs identified and number of RPs, out of the 80 expressed by the human 
genome, which are targeted by each miRNA. The results shown were generated using the 
online platforms miRWalk (Dweep et al., 2014) and miRNet (Fan et al., 2016).  
D-I. miR-129-5p expression in patient samples from 6 cancer types. D. breast cancer, E. colon 
cancer, F. head & neck cancer, G. rectum cancer, H. hepatocellular cancer, I. prostate cancer. 
The gene expression data was retrieved from The Cancer Genome Atlas (TCGA) database. 
Blue boxes denote normal tissue, whereas red refers to tumor sample of the indicated cancer 
type.  
 
 
of the first RNAi therapy. Prominent 
examples of such onco-suppressor 
miRNAs include miR-34a, let-7 and 
miR-16-5p, shown to inhibit the 
oncogene RAS (Yamakuchi et al., 
2008), activate the onco-suppressor 
p53 (Cho, 2007), and block oncogenic 
signaling via VEGFA (Qu et al., 2017), 
respectively.  
To identify our candidate miRNAs, we 
undertook an in-silico approach with 
the aim to analyze all the potential 
interactions between the known 
miRNAs (as annotated in miRBase) 
and the 80 RPs expressed by the 
human genome. The available 
databases that contain miRNA-mRNA 
interactions incorporate either 
predicted (usually generated by an 
algorithm) or validated interactions 
(generated during wet-lab 
experiments). For a thorough analysis 
we opted to include data from both 
types of datasets, using two platforms: 
miRNet for validated interactions (Fan 
et al., 2016) and miRwalk for predicted 
interactions (Dweep et al., 2014). 
Surprisingly, we identified a small 
group of 10 miRNAs whose members 
are reported to target at least 12 
ribosomal proteins. Notably, four of 
those miRNAs seem to possess the 
ability to bind to more than 30 RPs  
 
 
encoding genes. This data suggests that 
the action of only a few miRNAs is 
adequate to modulate the expression of 
most RPs and thereby affect 
translation. Those miRNAs may 
represent potential biomolecules with 
anti-cancer activity. Such onco-
suppressor miRNAs are frequently 
downregulated or deleted in cancer 
cells, thus removing this barrier in 
tumor initiation and progression. To 
investigate whether our miRNAs are 
subjected to this kind of regulation, we 
performed an expression analysis of 
miR-129-5p in patient samples from 6 
cancers types (breast cancer, colon 
cancer, head & neck cancer, rectum 
cancer, hepatocellular cancer, and 
prostate cancer) (Fig1. D-I) by using 
the gene expression data deposited in 
The Cancer Genome Atlas (TCGA) 
database (Weinstein et al., 2013).  
Interestingly, we found that one of our 
candidate miRNAs, miR-129-5p is 
downregulated in all tested samples 
(Fig.1 D.). This is consistent with a 
hypothetical tumor-suppressor function 
of this miRNA and, likely, the anti-
cancer activity of miR-129-5p is 
mediated via targeting ribosome 
biogenesis. Conclusively, this 
approach has resulted in the 
identification of a group of miRNAs 
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with potential modulatory role in 
ribosome biogenesis and at least one 
miRNA that seems to possess the 
capacity to act, upon its 
pharmacological exploitation, as anti-
cancer therapeutic.  
Treating cancer remains a pressing 
medical problem worldwide. By 
integrating biological knowledge as 
well as bioinformatic analysis we can 
not only identify potential 
‘’druggable’’ targets but also discover 
pharmacological agents to block those 
targets. In this direction, our approach 
stems from the thorough understanding 
of ribosomal (de)regulation in cancer 
cells and integrates bioinformatic tools 
to identify miRNA molecules able to 
reverse the impaired translational 
activity of cancer cells. Indeed, our 
analysis suggests that at least 10 
miRNAs may have a potential 
modulatory role in ribosomal function. 
We hypothesized that some of those 
miRNAs will act as tumor suppressors 
and, as a proof of concept we analyzed 
the expression of miR-129-5p across 6 
cancer types. MiR-129-5p is 
consistently downregulated in cancer 
patients, suggesting that the miRNA 
exhibits potential anti-cancer activity. 
Thus, the delivery of miR-129-5p in 
patients will likely be associated with a 
beneficial therapeutic outcome and 
thereby, its study in cancer cell 
samples is highly interesting. 
However, a more thorough molecular 
analysis has to be carried out to 
pharmacologically exploit the 
possibility of successfully developing 
miRNAs as targeted anticancer 
therapeutics with increased efficacy 
and safety profiles in the clinical 
setting. In conclusion, this brief report 
provides a workflow for the 
identification of novel miRNA 
molecules with highly interesting 
properties in modulating ribosome 
function in cancer cells. 
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